Blog › ICP guides

Healthcare regulatory attorney on retainer: FDA regulatory advisory, HIPAA compliance, and federal healthcare program advisory on monthly retainer

August 6, 2026 · ~22 min read

A digital health company has developed a software-based clinical decision support tool that analyzes patient lab values and vital signs and generates recommended medication dosage adjustments for ICU physicians. The company’s regulatory affairs team classified the software as a clinical decision support (CDS) tool exempt from FDA oversight under the 21st Century Cures Act’s CDS exemption in 21 U.S.C. §360j(o) and launched the product commercially. Eighteen months after launch, the FDA issues a warning letter asserting that the software does not qualify for the CDS exemption because it acquires, processes, or analyzes medical device data and displays patient-specific information to healthcare providers for use in diagnosis, treatment, or prevention of disease — making it a Software as a Medical Device (SaMD) subject to FDA premarket review requirements — and that the company has been marketing an unapproved medical device in violation of 21 U.S.C. §331(a).

The company engages a healthcare regulatory attorney to manage the FDA warning letter response. The attorney’s analysis of the CDS exemption requirements under 21 U.S.C. §360j(o) identifies that the company’s software does not satisfy all four statutory criteria for CDS exemption: while the software does not replace the clinical judgment of a healthcare professional and does display the basis for its recommendations in a manner that allows the clinician to independently review the basis, the software acquires and analyzes medical device data (ICU monitor vital sign streams constitute data from medical devices) and does not limit its output to general reference information that the intended user could review independently. The attorney advises that the company faces a choice between seeking substantial equivalence to a legally marketed predicate device through a 510(k) premarket notification or pursuing de novo classification as a novel device without a predicate, and that FDA warning letter response timelines (typically 15 business days for the initial written response) require immediate engagement with FDA to avoid escalation to a consent decree or seizure action.

Healthcare regulatory attorneys on monthly retainer — J.D.s specializing in FDA regulatory law, HIPAA compliance, and federal healthcare program compliance, often with prior FDA, OCR, or OIG experience — do a substantial share of their highest-value advisory work between FDA submissions, OCR investigations, and OIG audits. This guide covers FDA regulatory advisory, HIPAA compliance advisory, and federal healthcare program compliance: the legal frameworks behind each service area, the applicable federal statutes and regulations that govern the advisory, and how to structure a retainer agreement that makes the ongoing regulatory advisory work visible between enforcement and submission milestones.

FDA regulatory advisory

FDA regulatory advisory is the retainer function that manages the client’s interactions with the Food and Drug Administration across the device or drug product lifecycle: determining the appropriate regulatory pathway for new products, preparing and managing premarket submissions, responding to FDA information requests and deficiency letters, and advising on post-market surveillance and compliance obligations. For medical device companies, the three primary premarket pathways are the 510(k) premarket notification for Class II devices that are substantially equivalent to a legally marketed predicate, the de novo classification petition for novel Class II devices without a predicate, and the Premarket Approval (PMA) application for Class III devices.

510(k) premarket notification strategy

The 510(k) premarket notification pathway under 21 U.S.C. §510(k) allows a medical device manufacturer to obtain FDA clearance to market a new device by demonstrating that the new device is substantially equivalent to a legally marketed predicate device that was on the market before May 28, 1976, or has itself been cleared through the 510(k) process. Substantial equivalence requires that the new device have the same intended use as the predicate and either the same technological characteristics as the predicate, or different technological characteristics that do not raise new questions of safety and effectiveness and the device is at least as safe and effective as the predicate.

Predicate device selection is the most strategically significant decision in 510(k) development. The retained healthcare regulatory attorney advising on 510(k) strategy evaluates multiple potential predicate candidates from the FDA 510(k) database to identify the predicate that most closely matches the new device’s intended use and technological characteristics. A predicate with a broad intended use statement supports a broad clearance for the new device; a predicate with a narrow intended use statement limits the scope of the new device’s clearance. Where no single predicate provides a strong match for both intended use and technological characteristics, the attorney evaluates whether a split-predicate approach (using one predicate for intended use and a second, different predicate for technological characteristics) is defensible under FDA’s substantial equivalence framework — an approach FDA has scrutinized following the Vilain v. United States decision and FDA’s 2019 guidance on the use of split predicates in 510(k)s. The attorney also evaluates whether the new device’s software features, AI/ML algorithms, or novel materials create technological characteristic differences that trigger the need for performance testing data to demonstrate that the differences do not raise new questions of safety and effectiveness.

FDA pre-submission (Q-Sub) meeting program under 21 CFR Part 812 and FDA’s Q-Sub guidance allows device sponsors to request interactive feedback from FDA on proposed regulatory strategies, proposed clinical trial designs, and proposed premarket submission content before the formal 510(k) or PMA submission is made. Q-Sub meetings are particularly valuable for novel device designs, AI/ML-based SaMD, and device-drug combination products where the regulatory pathway and submission requirements are not clearly established by prior FDA clearances or approvals. The retained healthcare regulatory attorney managing a Q-Sub engagement prepares the Q-Sub meeting package (including a device description, proposed regulatory pathway and predicate selection rationale, specific questions for FDA, and proposed study designs or testing protocols where applicable), coordinates the client’s response to FDA’s written Q-Sub response, and advises on how FDA’s Q-Sub feedback should be incorporated into the premarket submission strategy. Q-Sub meeting requests typically receive FDA written responses within 90 days; in-person or teleconference meetings are available for certain Q-Sub types.

De novo classification under 21 U.S.C. §513(f)(2) is the appropriate pathway for novel medical devices of low to moderate risk that are not substantially equivalent to any legally marketed predicate. Unlike the 510(k) process, which requires demonstration of substantial equivalence to an existing device, the de novo pathway involves a risk-based classification determination by FDA that establishes the device as a new regulatory classification with special controls sufficient to provide a reasonable assurance of safety and effectiveness. A successful de novo classification creates a new predicate that can be used by future 510(k) applicants. The retained healthcare regulatory attorney advising on de novo strategy evaluates whether the device’s risk profile supports a de novo classification (de novo is appropriate for Class II devices; devices with higher risk profiles that cannot be adequately controlled by special controls require PMA), develops the special controls that the de novo petition will propose (performance testing standards, labeling requirements, post-market surveillance obligations), and manages FDA’s interactive review process for the de novo petition, which typically includes substantive FDA questions and feedback cycles before a de novo classification order is issued.

Premarket Approval (PMA) advisory for Class III devices

Premarket Approval under 21 U.S.C. §360e is the most rigorous FDA premarket pathway, applicable to Class III medical devices (devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury) for which general controls and special controls alone are insufficient to provide a reasonable assurance of safety and effectiveness. PMA approval requires valid scientific evidence (typically one or more well-controlled clinical investigations) demonstrating a reasonable assurance that the device is safe and effective for its intended use.

Investigational Device Exemption (IDE) advisory under 21 CFR Part 812 governs the clinical investigations of significant risk devices that require an IDE application approved by FDA and an Institutional Review Board (IRB) before the investigation begins. The retained healthcare regulatory attorney advising on IDE strategy reviews the proposed clinical protocol for compliance with 21 CFR Part 812 requirements (informed consent under 21 CFR Part 50, IRB review under 21 CFR Part 56, investigation plan content requirements under 21 CFR §812.25), identifies whether the proposed investigation qualifies as a significant risk device study requiring a full IDE or a non-significant risk device study exempt from the FDA IDE application requirement, and advises on the IDE application content including the device description, proposed investigations, a risk analysis, and the monitoring plan for IDE compliance.

Modular PMA submission strategy allows sponsors to submit completed sections of a PMA application to FDA for review before the entire application is completed, enabling FDA to begin its substantive review of the manufacturing, non-clinical, and preclinical sections while clinical data collection is ongoing. The retained healthcare regulatory attorney advising on a modular PMA strategy identifies which modules can be submitted early (manufacturing information, preclinical bench testing data, biocompatibility data), coordinates with FDA’s PMA review division to confirm that modular submission is available for the device type, and manages the submission timeline to align early module submissions with anticipated clinical data completion dates.

HIPAA compliance advisory

HIPAA compliance advisory is the retainer function that manages the client’s obligations under the Health Insurance Portability and Accountability Act of 1996 as implemented in the HIPAA Privacy Rule (45 CFR Part 164, Subpart E), the HIPAA Security Rule (45 CFR Part 164, Subpart C), and the HIPAA Breach Notification Rule (45 CFR Part 164, Subpart D). The HIPAA rules impose compliance obligations on covered entities (healthcare providers, health plans, and healthcare clearinghouses) and their business associates (persons or entities that perform functions involving the creation, receipt, maintenance, or transmission of protected health information (PHI) on behalf of a covered entity).

HIPAA Security Rule risk analysis and implementation specification advisory

The HIPAA Security Rule under 45 CFR Part 164, Subpart C requires covered entities and business associates to implement administrative, physical, and technical safeguards to protect electronic protected health information (ePHI). The Security Rule distinguishes between required implementation specifications (which must be implemented as stated) and addressable implementation specifications (which must be implemented if reasonable and appropriate, or the covered entity must document why the specification is not reasonable and appropriate and implement an equivalent alternative measure).

Security risk analysis under 45 CFR §164.308(a)(1)(ii)(A) is a required administrative safeguard that requires covered entities and business associates to conduct an accurate and thorough assessment of the potential risks and vulnerabilities to the confidentiality, integrity, and availability of ePHI held by the covered entity. The HHS Office for Civil Rights (OCR) has identified the failure to conduct a compliant security risk analysis as the most frequently cited HIPAA violation in OCR enforcement actions and resolution agreements. The retained healthcare regulatory attorney advising on Security Rule compliance develops a security risk analysis methodology that satisfies the seven elements identified in OCR’s guidance on risk analysis (scope of the analysis, data collection, identification of reasonably anticipated threats to ePHI, identification of reasonably anticipated vulnerabilities to ePHI, assessment of current security measures, determination of the likelihood of threat occurrence, determination of the potential impact of threat occurrence), coordinates the risk analysis documentation with the client’s IT security team, and advises on the risk management plan required to implement security measures sufficient to reduce the identified risks to a reasonable and appropriate level under 45 CFR §164.308(a)(1)(ii)(B).

Business Associate Agreement (BAA) advisory under 45 CFR §§164.308(b) and 164.502(e) is the contractual mechanism through which covered entities and business associates document their HIPAA compliance obligations. A business associate agreement must be executed before a business associate creates, receives, maintains, or transmits PHI on behalf of a covered entity; the BAA must include the required elements specified in 45 CFR §164.504(e), including a description of the permitted and required uses and disclosures of PHI, a requirement that the business associate implement appropriate safeguards, an obligation to report breaches of unsecured PHI, and a requirement that subcontractors who receive PHI from the business associate agree to the same restrictions and conditions. The retained healthcare regulatory attorney advising on BAA scope evaluates each cloud infrastructure, EHR platform, analytics vendor, and technology service provider that may receive or process PHI to determine whether the vendor is a business associate requiring a BAA (as opposed to a conduit for PHI transmission that does not require a BAA), negotiates BAA provisions with vendors whose standard BAA forms are inadequate for the client’s risk profile, and advises on BAA provisions covering the business associate’s use of subcontractors (chain BAA requirements under 45 CFR §164.308(b)(2)).

HIPAA Breach Notification Rule and OCR investigation response

The HIPAA Breach Notification Rule under 45 CFR Part 164, Subpart D requires covered entities and business associates to notify affected individuals, the HHS Secretary, and (for breaches affecting 500 or more individuals in a state or jurisdiction) prominent media outlets of a breach of unsecured PHI. A breach is the acquisition, access, use, or disclosure of PHI in a manner not permitted under the Privacy Rule that compromises the security or privacy of the PHI — subject to a presumption (rebuttable by a risk-of-harm analysis) that any impermissible use or disclosure of PHI is a breach.

Risk-of-harm analysis under 45 CFR §164.402 is the four-factor analysis that a covered entity or business associate must perform to determine whether an impermissible use or disclosure of PHI constitutes a reportable breach. The four factors are: (1) the nature and extent of the PHI involved, including the types of identifiers and the likelihood of re-identification; (2) the unauthorized person who used the PHI or to whom the disclosure was made; (3) whether the PHI was actually acquired or viewed; and (4) the extent to which the risk has been mitigated by the covered entity or business associate (for example, through the execution of a confidentiality agreement and satisfactory assurances from the recipient that the PHI has been destroyed). The retained healthcare regulatory attorney advising on a potential breach applies the four-factor risk-of-harm analysis to the specific facts of each security incident, documents the analysis and conclusion, and advises on whether the risk-of-harm analysis supports a determination that the presumption of breach has been rebutted (no notification required) or cannot be rebutted (breach notification required within 60 days of discovery under 45 CFR §164.412 for individual and media notification, and on the annual log for HHS notification for breaches affecting fewer than 500 individuals).

OCR investigation response begins when OCR sends a data request letter following the receipt of a complaint or a large breach notification (500 or more affected individuals automatically triggers OCR review). OCR’s investigation process begins with a data request for the covered entity’s policies and procedures, documentation of its HIPAA Security Rule risk analysis, its risk management plan, and its workforce training records. The retained healthcare regulatory attorney managing an OCR investigation develops the response strategy: determining which documents to produce and which to withhold under attorney-client privilege or work product doctrine, coordinating the client’s collection of responsive documents, preparing cover letters that contextualize the client’s compliance program, and advising on whether OCR’s investigation is likely to result in a finding of no violation, a corrective action plan (CAP), or a civil money penalty resolution agreement.

Federal healthcare program compliance

Federal healthcare program compliance is the retainer function that manages the client’s obligations under the federal fraud and abuse laws that govern financial relationships between healthcare providers, suppliers, and referral sources in connection with federal healthcare programs (Medicare, Medicaid, CHIP, and TRICARE): the Anti-Kickback Statute, the Stark Law self-referral prohibition, and the False Claims Act. Violations of these statutes expose healthcare entities to criminal prosecution, civil money penalties, exclusion from federal healthcare programs, and qui tam relator litigation.

Anti-Kickback Statute safe harbor advisory

The Anti-Kickback Statute under 42 U.S.C. §1320a-7b(b) prohibits the knowing and willful solicitation, receipt, offer, or payment of remuneration (anything of value, in cash or in kind) in return for referring, recommending, or arranging for the referral of an individual for an item or service reimbursable under a federal healthcare program, or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any item or service reimbursable under a federal healthcare program. The statute’s scope is broad: remuneration includes any transfer of value, and the prohibition applies even where the remuneration is offered or paid for legitimate services if one purpose of the remuneration is to induce referrals.

Regulatory safe harbor analysis under 42 CFR §1001.952 provides a set of safe harbors that protect financial arrangements from Anti-Kickback Statute liability if the arrangement satisfies all elements of an applicable safe harbor. Safe harbors most frequently applicable in advisory practice include: the personal services and management contracts safe harbor (§1001.952(d)) — which requires that the arrangement be set out in a written agreement signed by the parties, cover all of the services the agent provides to the principal for the term of the agreement, specify the aggregate compensation to be paid over the term of the agreement (which must be set in advance), the compensation not be determined in a manner that takes into account the volume or value of referrals, and the services performed not involve the counseling or promotion of illegal activity; the space rental safe harbor (§1001.952(b)) and equipment rental safe harbor (§1001.952(c)) — which impose parallel requirements for written agreements, fair market value rental rates, and compensation not determined by reference to the volume or value of referrals; and the electronic health records items and services safe harbor (§1001.952(y)) — which permits donors (other than laboratories) to provide EHR software, information technology, and training to physician practices if the donation is not conditioned on the physician’s referral of patients and the donor does not restrict the physician’s ability to use the donated technology with other healthcare entities. The retained healthcare regulatory attorney performing a safe harbor analysis identifies which safe harbors are potentially applicable to a proposed arrangement, analyzes each element of the applicable safe harbor against the proposed arrangement’s terms, and advises on which elements require modification to achieve safe harbor protection.

Stark Law self-referral prohibition and exception advisory

The Stark Law under 42 U.S.C. §1395nn prohibits a physician from making a referral to an entity for the furnishing of designated health services (DHS) reimbursable under Medicare if the physician (or an immediate family member of the physician) has a financial relationship with the entity, unless the financial relationship fits within a statutory or regulatory exception. Unlike the Anti-Kickback Statute (which requires proof of knowing and willful conduct), Stark Law is a strict liability statute: a referral that does not fit within an applicable exception violates the statute regardless of the parties’ intent or knowledge.

In-office ancillary services exception under 42 U.S.C. §1395nn(b)(2) is the exception most frequently applicable to physician group practices that provide designated health services in connection with their primary physician services. The exception permits a physician to refer patients to the physician’s own group practice for DHS if the services are furnished (1) by the referring physician personally, by another physician in the group practice, or by an individual who is supervised by the referring physician or another physician in the group practice and who is an employee, leased employee, or independent contractor of the group practice; (2) in a building in which the referring physician furnishes substantially all of the physician services that the physician personally furnishes to patients of the physician, or in another centralized location of the group practice; and (3) billed by the physician performing or supervising the services, by the group practice through a billing number assigned to the group practice, or by an entity wholly owned by the physician or group practice. The retained healthcare regulatory attorney analyzing a proposed ancillary services arrangement maps the proposed arrangement against each element of the in-office ancillary services exception, identifies which elements are satisfied and which require modification (for example, whether the proposed service location qualifies as a centralized location of the group practice under the regulatory definition at 42 CFR §411.355(b)(2)), and advises on the documentation required to demonstrate ongoing compliance with the exception.

False Claims Act implied certification advisory

The False Claims Act under 31 U.S.C. §§3729-3733 imposes civil liability on persons who knowingly present or cause to be presented a false or fraudulent claim for payment or approval to the federal government, or who knowingly make or use a false record or statement material to a false or fraudulent claim. The FCA’s qui tam provision under 31 U.S.C. §3730(b) allows private individuals (relators) to file FCA complaints on behalf of the United States and receive a share (15% to 30%) of any government recovery — making the FCA the primary federal mechanism for healthcare fraud enforcement and the basis for the majority of civil healthcare fraud recoveries obtained by the Department of Justice.

Implied certification liability under the Supreme Court’s decision in Universal Health Services, Inc. v. United States ex rel. Escobar, 579 U.S. 176 (2016), extends FCA liability beyond express false certifications to situations where the claimant submits a claim that implicitly represents compliance with conditions of payment without expressly certifying compliance. Under Escobar, a healthcare provider submitting a Medicare or Medicaid claim implicitly represents that it has complied with the conditions of payment applicable to the claim — and if the provider has failed to comply with a material condition of payment (a condition that the government would likely not have paid the claim had it known of the noncompliance), the submission of the claim constitutes a false representation for FCA purposes. The retained healthcare regulatory attorney advising on FCA implied certification risk evaluates the client’s billing practices against applicable Medicare and Medicaid conditions of participation, conditions of coverage, and provider enrollment requirements to identify potential implied certification exposures — for example, where a hospital has been billing Medicare for services provided by physicians who are not compliant with applicable supervision requirements, or where a clinical laboratory has been billing Medicare for tests ordered in violation of the applicable Anti-Kickback Statute safe harbor requirements (which are expressly designated as conditions of payment under the Medicare program). The Escobar materiality standard requires that the noncompliance be material to the government’s payment decision — a high bar that the attorney evaluates by reference to whether the government has consistently refused to pay claims with the identified noncompliance, whether the regulatory requirement was specifically designated as a condition of payment, and whether the government was aware of the noncompliance and continued to pay — providing a framework for distinguishing noncompliance that creates genuine FCA exposure from technical regulatory deficiencies that are unlikely to support FCA liability.

The retained healthcare regulatory attorney advising on FCA compliance reviews the client’s Corporate Compliance Program against OIG’s Compliance Program Guidance for the relevant provider type (hospitals, physician practices, clinical laboratories, medical device manufacturers), evaluates the effectiveness of the client’s internal reporting and investigation procedures for identifying potential FCA exposures, and advises on the OIG’s voluntary self-disclosure protocol when the client has identified a potential overpayment or fraud that may constitute an FCA violation — including the quantification of the overpayment required to be returned to CMS within 60 days of identification under the Affordable Care Act’s 60-day rule (42 U.S.C. §1320a-7k(d)).

Tracking healthcare regulatory retainer hours with a shared dashboard

Healthcare regulatory attorneys on monthly retainer perform the compliance advisory work between FDA submissions, OCR investigations, and OIG audits that prevents those enforcement events from occurring in the first place — or positions the client to respond effectively when they do. That advisory work (predicate device selection analysis, Security Rule risk analysis management, Anti-Kickback safe harbor compliance memos, Stark Law exception mapping, FCA implied certification risk assessments) generates no visible artifact for the client’s compliance officer or executive team until an enforcement action materializes or a submission deadline approaches.

A retainer dashboard that gives the client’s compliance officer real-time visibility into the healthcare regulatory attorney’s time allocation — which regulatory matters consumed the month’s hours, which FDA submission milestones are approaching, which HIPAA vendor BAA gaps were identified and remediated — transforms the retainer from an opaque monthly fee into a documented compliance advisory record. The work log that accompanies each entry (regulatory matter, applicable federal statute or regulation, finding or recommended compliance position, hours spent) provides the client’s compliance team with a running account of the regulatory advisory activity that explains the retainer fee in terms of specific compliance outcomes and regulatory risk mitigation.

HourTab provides a public, no-login retainer dashboard URL that the healthcare regulatory attorney sends to the client once and the client’s compliance officer bookmarks. The dashboard shows the current retainer burn-down (hours used vs. hours remaining in the cycle), a chronological work log of entries from the healthcare regulatory attorney, and the reset date for the next billing cycle — eliminating the monthly “how many hours do I have left?” inquiry and giving the compliance officer a self-serve view of the retainer utilization between the attorney’s monthly billing statements.

Frequently asked questions

What does a healthcare regulatory attorney on retainer typically do?

A healthcare regulatory attorney (a J.D. specializing in FDA regulatory law, HIPAA compliance, and federal healthcare program compliance) on monthly retainer provides ongoing advisory across three principal service areas: FDA regulatory advisory (510(k) premarket notification strategy, de novo classification, PMA advisory, and Q-Sub meeting management); HIPAA compliance advisory (Security Rule risk analysis, Business Associate Agreement scope and negotiation, Breach Notification Rule risk-of-harm analysis, and OCR investigation response); and federal healthcare program compliance (Anti-Kickback Statute safe harbor analysis, Stark Law self-referral exception advisory, and False Claims Act implied certification risk assessment and voluntary self-disclosure advisory). The retained attorney reviews new product development plans for FDA regulatory pathway implications before design lock, advises on vendor contracts for HIPAA compliance risk, and monitors regulatory enforcement trends to identify compliance exposure before OIG or OCR investigations are opened.

What healthcare regulatory advisory work is most commonly underlogged?

The most systematically underlogged categories are: FDA pre-submission advisory (regulatory pathway analysis and Q-Sub meeting management before any formal submission, takes 6 to 20 hours per product cycle and produces no visible output until the formal 510(k) or PMA is filed); HIPAA Security Rule risk analysis management (advising IT and security teams on risk analysis methodology, implementation specification classification, and BAA gap analysis, takes 15 to 40 hours per year and produces no visible output until an OCR investigation or breach event); Anti-Kickback safe harbor structuring (analyzing whether proposed physician or vendor financial arrangements satisfy all elements of applicable safe harbors, takes 8 to 20 hours per arrangement review and is invisible until an OIG investigation or qui tam complaint); and False Claims Act implied certification advisory (evaluating billing practices against applicable conditions of payment for FCA exposure under Escobar, takes 10 to 30 hours per billing code review and produces no visible output until a government investigation materializes).

What should a healthcare regulatory attorney retainer agreement include?

Healthcare regulatory attorney retainer agreements should specify: the services covered (FDA regulatory advisory, HIPAA compliance advisory, federal healthcare program compliance, or a defined combination); the regulatory frameworks that govern the advisory (FDCA 21 U.S.C. §§301-399i; FDA QSR 21 CFR Part 820; HIPAA Privacy Rule 45 CFR Part 164 Subpart E; HIPAA Security Rule 45 CFR Part 164 Subpart C; HIPAA Breach Notification Rule 45 CFR Part 164 Subpart D; Anti-Kickback Statute 42 U.S.C. §1320a-7b(b); Stark Law 42 U.S.C. §1395nn; False Claims Act 31 U.S.C. §§3729-3733); the deliverables format (FDA pathway memos, predicate analysis, Q-Sub meeting packages, HIPAA risk analysis documentation, BAA redlines, Anti-Kickback safe harbor memos, Stark exception analysis, FCA advisory memos); and the work log format that gives the client’s compliance officer visibility into the regulatory advisory activity between FDA submissions and enforcement milestones.

What are typical retainer rates for healthcare regulatory attorneys?

Healthcare regulatory associates and counsel with 3 to 7 years of experience typically bill at $325 to $550 per hour. Senior healthcare regulatory partners and former FDA or OCR officials with 8 or more years of experience typically bill at $500 to $900 per hour. Monthly retainer amounts for FDA regulatory advisory typically range from $5,000 to $20,000 per month; HIPAA compliance retainers typically range from $4,000 to $15,000 per month; Anti-Kickback and Stark Law compliance retainers typically range from $6,000 to $25,000 per month. OCR investigation and OIG audit response retainers during active investigation phases typically range from $15,000 to $75,000 or more per month.

How should healthcare regulatory attorney retainer hours be logged?

Healthcare regulatory retainer work log entries should capture: the regulatory matter (FDA 510(k) advisory, HIPAA Security Rule risk analysis, Anti-Kickback safe harbor analysis, Stark Law exception advisory, False Claims Act compliance review), the specific regulatory task performed, the applicable federal statute or regulation analyzed (including the specific CFR section), and the finding or recommended compliance position. A useful format is: [Regulatory Matter] + [Specific regulatory task] + [Federal statute or regulation analyzed] + [Finding or recommended position]. Entries that identify the specific HIPAA implementation specification analyzed, the BAA vendor gap and remediation step, and the Anti-Kickback safe harbor element-by-element analysis transform the healthcare regulatory retainer from a general compliance advisory agreement into a documented advisory record between OCR investigations, FDA submissions, and OIG audits.

HourTab gives healthcare regulatory attorneys a public retainer dashboard URL their clients can bookmark — no client login, no portal, just a URL that shows hours used, hours remaining, and the work log behind the retainer. Learn more at hourtab.com.